linjc16/ctgov huggingface dataset:
Effectiveness of CC VS Aerobic Exercise for Strengthening and Improving QOL in Post Stroke Patients

Study Overview
=================
Brief Summary
-----------------
To determine the effects of closed chain versus aerobic exercise for strengthening and improving quality of life in post stroke patients

Official Title
-----------------
Effectiveness of Closed Chain Versus Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Diagnostic Test: Closed Chain
* Diagnostic Test: Aerobic Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemiplegic post stroke patients (either left or right side) Patients of both gender Age range in between 40 to 60 Patient with cognitive functioning Exclusion Criteria: History of any cardiac problem Recurrent stroke Any kind of disability or amputated limb Neurological conditions like Parkinsonism, epilepsy and spinal cord injury. Any kind of fracture or dislocation history.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Closed Chain<br> | Diagnostic Test: Closed Chain<br>* Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients<br>|
| Other: Aerobic Exercise<br> | Diagnostic Test: Aerobic Exercise<br>* Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barthel Index Scale |  | 6 Months | 
| The Oxford Scale | The Oxford Scale to improve QOL in Post Stroke Patients | 6 Months |
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about infectious complications in patients affected by B-cell acute lymphoblastic leukemia treated with inotuzumab-ozogamicin (INO). The main question it aims to answer is: • incidence of infectious complications (bacterial, fungal, viral) in patients receiving inotuzumab ozogamicin up to 60 days after the end of treatment

Detailed Description
-----------------
The present study is a multicenter, retrospective, observational clinical-epidemiological study on infectious complications (bacterial, fungal, viral) in patients receiving inotuzumab ozogamicin (INO). The study collects data from about 20 Hematologic Centers of the GIMEMA Group treating B-cell acute lymphoblastic leukemia (ALL) patients with inotuzuumab-ozogamicin (INO) over the last 5 years (2018-2023), according to the authorized indications and not included in interventional clinical trials (randomized or not randomized).

Official Title
-----------------
Multicenter Retrospective Observational Study Analyzing Infective Complications and the Clinical Outcome of Patients With Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin (INO-FIRST)

Conditions
-----------------
Acute Lymphoblastic Leukemia, Infections, Bacterial Infections, Viral Infection, Fungal Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (>18 years old) Patients with relapsed/refractory CD-22 positive B-ALL treated with INO or with relapsed/refractory CD22 positive and Ph-positive B-ALL treated with INO after failing at least one TKI inhibitor Signed informed consent if applicable. Exclusion Criteria: • Patients treated with INO in interventional clinical trials.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of clinically or microbiologically documented infectious complications in patients receiving inotuzumab ozogamicin (INO) up to 60 days after the end of treatment (last dose administered) | To estimate the rate of clinically or microbiologically documented infectious complications (bacterial, fungal, viral) in acute lymphoblastic leukemia patients receiving inotuzumab ozogamicin (INO) up to 60 days after the end of treatment (last dose administered). | 5 months |
A Novel Point-to-care Method for Fast Evaluation of Viscoelastic Hemostasis Analysis

Study Overview
=================
Brief Summary
-----------------
This study compares the results of the existing coagulation monitoring technology to the Ultrasound-based viscoelastic hemostasis analysis, a new method, using small amount of extra blood obtained during routine blood draws in surgery patients.

Detailed Description
-----------------
Ultrasound-based viscoelastic hemostasis analysis is a novel POC diagnostic method, which is suitable for use in surgical care settings. The novel viscoelastic hemostasis analysis uses ultrasound guided waves to characterize the dynamic changes in viscoelastic properties of a blood sample during coagulation and clot lysis, which will be the surgical assay for monitoring hemostasis during major surgical procedures in adult patients. This single-center, prospective, observational pilot study will evaluate the analytical performance as well as compared to standard coagulation tests and comparable measures using conventional viscoelastic testing methods.

Official Title
-----------------
A Novel Point-to-care Method for Fast Evaluation of Viscoelastic Hemostasis Analysis

Conditions
-----------------
Perioperative Period

Intervention / Treatment
-----------------
* Procedure: Blood specimen collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is scheduled for surgery with general surgery Subject is 18 years or order Subject requires routine TEG measurement Exclusion Criteria: Subject is unwilling to participate Subject is unable to sign a consent form Subject is unsuitable for blood drawing Subject is unsuitable for this study in the opinion of the anesthesiologist

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| General anesthesia Patients<br>Subjects experiencing general anesthesia such that viscoelastic testing is performed to assess coagulopathy. | Procedure: Blood specimen collection<br>* Routinely collect citrate blood and native blood from patients as required by their condition.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the novel viscoelastic hemostasis analysis results to TEG results | Coagulation function assessed by the novel viscoelastic hemostasis analysis and TEG | 1 day | 
| Comparison of the novel viscoelastic hemostasis analysis results to standard coagulation test results | Coagulation function assessed by the novel viscoelastic hemostasis analysis and standard coagulation test | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood coagulation, blood coagulation tests
Interventional Therapy of Tracheal Stenosis

Study Overview
=================
Brief Summary
-----------------
After respiratory weaning, decannulation is sought. To do this, the tracheal cannula is first unblocked, so that patients no longer breathe in and out through the cannula, but (at least partially) passing the cannula by the natural route. In the presence of tracheal stenosis there is increased breathing effort, possibly restlessness and stridor. This constellation of symptoms suggests the suspicion of tracheal stenosis, so in the next step a tracheoscopy is performed to confirm or exclude tracheal stenosis. In case of symptomatic tracheal stenosis and at least 30-50% stenosis of the trachea (clinical symptoms can be expected from a 30-50% stenosis) then appropriate therapy (here: cryotherapy, other techniques only in exceptional cases) is planned. The goal is to be able to remove the tracheal cannula (long term) after successful therapy, so that patients do not have to be permanently provided with a tracheal cannula. There is no definitive/evidence-based standard therapy for the treatment of tracheal stenosis. Cryotherapy is a gentle therapy that has already been applied and described for the treatment of tracheal stenosis (see above). The examination is performed as part of an analgesic dose, as is routine for a bronchoscopy (in-house SOP). After treatment, a follow-up is planned for about 10 days later.

Official Title
-----------------
Interventional Therapy of Tracheal Stenosis After Percutaneous Tracheotomia

Conditions
-----------------
Tracheal Stenosis Following Tracheostomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tracheal stenosis after percutaneous tracheotomy. Exclusion Criteria: Pregnant or breast-feeding women of childbearing potential who refuse pregnancy test. lack of consent to participate in the study. surgical tracheotomy. Involvement of the larynx (above the first tracheal brace).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decannulation | Rate of successful decannulations after intervention up to discharge from inpatient treatment. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical success | technical success of the intervention (endoscopically not clinically relevant tracheal stenosis). | 12 months | 
| Reintervention(s) | Number of interventions required. | 12 months | 
| Type of intervention | Type of intervention(s) (cyroablation, APC, loop extraction). | 12 months | 
| Clinical success | Clinical success (no stridor, no dyspnoea). | 12 months | 
| Additional treatment | Number of patients requiring surgical treatment/stent. | 12 months |
Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms

Study Overview
=================
Brief Summary
-----------------
This registry study will investigate the incidence of and outcomes associated with clopidogrel hyper-responsive patients treated at Methodist Dallas Medical Center, beginning in January 2018, who suffered cerebral aneurysms.

Detailed Description
-----------------
This registry study will investigate the incidence of and outcomes associated with clopidogrel hyper-responsive patients treated at Methodist Dallas Medical Center, beginning in January 2018, who suffered cerebral aneurysms. Perioperative and short-term clinical data will be obtained from electronic medical records. All the data variables will be documented in an Excel sheet (Appendix B). This section will provide an overview of the data collected which will include, but are not limited to, the following: • Pre-Operative Information: Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; etc.).

Official Title
-----------------
Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms

Conditions
-----------------
Cerebral Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Diagnosed with cerebral aneurysms (i.e. ICD-10 i67.1) Pre-intervention treatment with clopidogrel Exclusion Criteria: Does not meet inclusion criteria specified in 3.1

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Registry Evaluation | The demographic characteristics, treatment strategies, incidence, and outcomes in patients hyper-responsive to clopidogrel. | 90 days |
Comparison of Innovative Rehabilitation Treatments and Examination of Their Effectiveness in Stroke Patients

Study Overview
=================
Brief Summary
-----------------
We perform a comparison of several groups. We would like to determine how robotic and virtual therapy is most effective in the treatment of stroke patients. We place great emphasis on walking speed, quality of life, coordination and changes in walking distance.

Official Title
-----------------
Comparison of Innovative Rehabilitation Treatments and Examination of Their Effectiveness in Stroke Patients

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: Robot
* Other: Fizio
* Other: EXE1
* Other: EXE2
* Other: EXE+ROB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: post stroke 6MWT : 120> minimum after stroke 3 days be a stroke patient first stroke hemiplegia Exclusion Criteria: multiple strokes, inability to stand and walk, cognitive function disorder does not reach 50 meters with a minimal walking aid Alcohol Sever heart problem sever demeanor alcoholism drug problems Drug

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Robotic<br>They performed training with a robot 15 times over 3 weeks. | Other: Robot<br>* You have to walk with a robot mounted on your lower limb. To move, to change direction.<br>* Other names: ROB;|
| Experimental: Fizio<br>They receive physiotherapy treatment. | Other: Fizio<br>* Patients do state-funded physical therapy.<br>|
| Experimental: EXE1<br>Virtual reality treatment is performed once a day. | Other: EXE1<br>* Patients undergo intensive virtual reality therapy once a day.<br>|
| Experimental: EXE2<br>Virtual reality treatment is performed twice a day. | Other: EXE2<br>* Patients undergo intensive virtual reality therapy twice a day.<br>|
| Experimental: EXE+ROB<br>Virtual and robotic treatments are performed once a day. | Other: EXE+ROB<br>* The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mRS score |  | 3 weeks (0-5 score, high score better) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barthel index score |  | 3 weeks | 
| Berg balance score |  | 3 weeks (0-30, high score better) | 
| 6MWT | meter | 3 weeks | 
| 10m gait speed | m/s | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
robotic, stroke, rehabilitation, virtual rehabilitation
Role of Inflammatory Markers in Sepsis

Study Overview
=================
Brief Summary
-----------------
A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Official Title
-----------------
Role of Inflammatory Markers Measured Using Flow Cytometry in the Diagnosis and Prognosis of Sepsis in Surgical Cancer Patients

Conditions
-----------------
Diagnostic

Intervention / Treatment
-----------------
* Diagnostic Test: Serology tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis Exclusion Criteria: Refusal of patient or patient guardian to participate. Intraoperative massive blood loss and massive blood transfusion Patients with impaired preoperative kidney or liver function tests

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Septic patients<br> | Diagnostic Test: Serology tests<br>* CD4, CD25, IL17<br>|
| Non Septic patients<br> | Diagnostic Test: Serology tests<br>* CD4, CD25, IL17<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the expression CD4 | Serology | 7 days | 
| To evaluate the expression CD25 | Serology | 7 days | 
| To evaluate the expression IL17 | Serology | 7 days |
Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research

Study Overview
=================
Brief Summary
-----------------
Clinical trials, specifically focused on anxiety disorder, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

Official Title
-----------------
Investigating Patterns in Enrollment and Engagement Among Individuals Coping With Anxiety Disorder

Conditions
-----------------
Anxiety Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old Diagnosis of anxiety disorder Able to comprehend the investigational nature of the protocol and provide informed consent Exclusion Criteria: Female patients who are currently pregnant or nursing Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. Inability to perform regular electronic reporting

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of anxiety disorder patients who decide to enroll in a clinical research |  | 3 months | 
| Rate of anxiety disorder patients who remain in clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anxiety disorder
Anatomical Variation in Rouvière's Sulcus

Study Overview
=================
Brief Summary
-----------------
Rouvière's sulcus is a 2-5 cm fissure lying on the lower face of the liver, between the right lobe and caudate process. Due to its extrabiliary location, Rouvière's Sulcus could be used as an anatomical landmark for safe laparoscopic cholecystectomy. In literature there's an high variability about Rouvière Sulcus prevalence and its anatomical variants.

Detailed Description
-----------------
The goal of this observational study is to evaluate the presence of Rouvière Sulcus in patients underwent laparoscopic cholecystectomy. The main questions it aims to answer are the prevalence and the anatomical variations of Rouvière's Sulcus and the variants of Rouvière's Sulcus which are catheghorized according to Singh and Prasad criteria. The following were considered secondary outcome: operative time expressed in minutes, biliary tract injuries according to Stewart's classification and Vascular injuries.

Official Title
-----------------
Anatomical Variation in Rouvière's Sulcus: a Cross-sectional Study

Conditions
-----------------
Rouvière's Sulcus

Intervention / Treatment
-----------------
* Procedure: Videolaparoscopic cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing videolaparoscopic cholecystectomy Exclusion Criteria: If the lower face of the right hepatic lobe and the main elements of the biliary tract cannot be clearly analyzed patients will be excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Videolaparoscopic cholecystectomy<br>Patients undergoing Videolaparoscopic cholecystectomy | Procedure: Videolaparoscopic cholecystectomy<br>* Evaluation of Rouvière's Sulcus Anatomical Variation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Rouvière's Sulcus |  | 2 years | 
| Anatomical variations in Rouvière's Sulcus | The variants of the Rouvière's Sulcus are catheghorized by the classification of Singh e Prasad. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operative time | Time expressed in minutes | 2 years | 
| Biliary tract injuries | Biliary tract injuries according to Stewart's classification. | 2 years | 
| Vascular injuries | Vascular injuries. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevalence Rouvière's Sulcus, Anatomical variations Rouvière's Sulcus